Nexalin Technology, Inc., a company focused on non-invasive brain stimulation for mental health, has received a deficiency notice from the Nasdaq Stock Market. The company is non-compliant with the minimum bid price requirement for continued listing on the exchange, putting its Nasdaq status at risk.
Key Takeaways
- Nexalin Technology has been notified by Nasdaq that it does not meet the minimum bid price requirement.
- The company has 180 days, until July 20, 2026, to regain compliance.
- Compliance requires the stock to close at $1.00 or higher for 10 consecutive trading days.
- Failure to comply could lead to delisting from the Nasdaq.
Nasdaq Bid Price Deficiency
The notification from Nasdaq, dated January 21, 2026, states that Nexalin Technology has failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. This triggers a compliance issue under Nasdaq Listing Rule 5550(a)(2).
Path to Compliance
Nexalin Technology has been granted a 180-day period, concluding on July 20, 2026, to rectify the situation. To regain compliance, the company’s stock must achieve a closing bid price of at least $1.00 for a minimum of 10 consecutive trading days. If the company fails to meet this threshold by the deadline, it may be granted additional time or face potential delisting.
Company’s Response and Outlook
The company has stated that the notification does not immediately impact its stock trading, which will continue on Nasdaq under the ticker "NXL." Nexalin Technology is actively monitoring its bid price and is exploring various strategies to improve its financial standing and operational results. The company aims to counteract the adverse effects on its trading price and resolve the deficiency. However, a reverse stock split is not currently being considered.
About Nexalin Technology
Nexalin Technology is dedicated to developing innovative neurostimulation products to address the global mental health crisis. Their non-invasive devices are designed to provide relief for mental health issues using bioelectronic medical technology. The company believes its devices can penetrate deep brain structures associated with mental health disorders, offering enhanced patient response without adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has received approval in China, Brazil, Oman, and Israel.
Sources
- Nexalin Technology Receives Nasdaq Listing Status, GlobeNewswire.
